MedTrace Logo

Endocrine Disrupting Chemicals and Hormones in ADHD

NCT04970303 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2021-07-21

No results posted yet for this study

Summary

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children and adolescents. Growth hormone and thyroid function are associated with both physical and neurocognitive development. Endocrine disrupting chemicals (EDCs) could disturb the normal function of endocrine systems, and further link to the pathophysiology of ADHD. In addition, whether methylphenidate for treating ADHD influences growth hormone and thyroid function of patients remains unclear.

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

DRUG

Methylphenidate

Retina or Concerta

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    lead OTHER

Principal Investigators

  • Liang-Jen Wang, MD, MPH, PhD · Chang Gung Memorial Hospital, Kaohsiung, Taiwan

Eligibility

Min Age
6 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-12
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04970303 on ClinicalTrials.gov